RTSM Resources
-
3 Study Areas Where Your IRT Vendor Should Do More
11/21/2024
Find out how advanced IRT systems now support diverse trial designs and how the expertise of RTSM vendors is crucial for tailoring solutions to trial needs and providing ongoing support.
-
Master Protocols: Implementing Effective Treatment Adaptations
8/25/2025
From balancing treatment ratios and managing eligibility to accommodating site-specific readiness and protocol amendments, a well-designed IRT system enables seamless transitions.
-
Navigating The AI And Regulatory Frontier For Clinical Operations, Supply
12/5/2025
AI is transforming clinical trials. Learn how strategic adoption and cultural readiness can unlock efficiency, resilience, and compliance in an evolving global landscape.
-
Why Amendments Break Trials and How Elosity R3 Fixes It
7/31/2026
Protocol amendments are inevitable. The challenge is managing them without disrupting trial execution.
-
Beyond the Acronyms: What Today's Trials Really Need From RTSM
12/4/2025
Consider how resin selection, process optimization, and system qualification create scalable workflows that meet evolving regulatory and operational demands in modern biomanufacturing.
-
What Is IRT And How Does It Impact Clinical Trials?
10/8/2026
Automated randomisation, blind protection, and demand-driven supply handling replace envelope-based methods and paper-based tracking, changing study management from first site activation onward.
-
How AI Is Reshaping RTSM Study Builds
6/4/2026
How Agentic RTSM cuts study build timelines by up to 80%, accelerating kickoff-to-UAT while maintaining compliance, quality, and auditability in clinical trials.
-
How Long Is Your RTSM Risk Mitigation List?
11/21/2024
While RTSM systems help reduce many of the risks in clinical trials, each trial’s unique setup necessitates a risk analysis to identify trial-specific challenges.
-
Emerging Biopharm Rapidly Sets Up Phase 1 Oncology Trial
1/16/2024
Uncover how an emerging biopharmaceutical company was able to expedite the initiation of a Phase 1 oncology trial for a novel treatment targeting relapsed/refractory multiple myeloma.
-
Finding The Optimal IRT/RTSM Design For Your Clinical Trial
10/4/2024
Determine the best IRT/RTSM design for your trial through consideration of the user, data collection, and future-proofing.